1. Introduction {#s0005}
===============

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS). Although the cause of the MS is unknown, the disease is characterized pathologically by early acute lesions made up of discrete areas of inflammatory demyelination that either resolve by remyelination or evolve into chronic lesions with associated axonal loss, oligodendroglial cell loss and glial scarring. Lesions of inflammatory demyelination may be visualized by MRI imaging of the CNS. Clinically, most patients have disease onset in young adulthood with characteristic symptom relapses and remissions (RRMS). Over time, RRMS may evolve to a secondary progressive (SPMS) phase with accrual of permanent disability. In about 10--15% of patients the disease course is primarily progressive from onset (PPMS). Available disease modifying therapies may prevent or delay disease progression through immunosuppression and immunomodulation ([@bb0030]). Once progressive disability is established, however, there are no therapies currently available to protect, repair, or regenerate neural tissue in order to restore neurological function ([@bb0150]). Common clinical manifestations of patients with SPMS or PPMS include motor weakness with progressive paralysis, sensory dysfunction, bladder/bowel dysfunction, coordination difficulties and cognitive decline. Cell-based therapies are currently under investigation to alleviate some of these clinical symptoms as a strategy to target progressive decline, which remains a major unmet need in MS.

Mesenchymal stem cells (MSCs) extracted from various tissues including bone marrow have multipotent mesodermal differentiation potential, but more importantly have demonstrated ability to promote tissue repair through the release of paracrine factors ([@bb0130]). Intravenous administration of MSCs or conditioned media derived from MSCs is protective against experimental autoimmune encephalomyelitis (EAE) in mice through immunomodulatory mechanisms ([@bb0010]; [@bb0155]; [@bb0160]; [@bb0165]; [@bb0195]), thus forming the preclinical basis for clinical safety testing of intravenous ([@bb0025]; [@bb0035]; [@bb0110]) or intrathecal ([@bb0095]; [@bb0135]; [@bb0190]) transplantation of autologous MSCs in patients with MS. MSCs are also capable of neuroprotection, promotion of oligodendrogenesis, and inhibition of gliosis, and thus may impact multiple aspects of MS pathology in the CNS ([@bb0020]; [@bb0105]; [@bb0170]; [@bb0175]; [@bb0185]; [@bb0200]).

MSC-derived neural progenitors (MSC-NPs) are a subpopulation of MSCs that exhibit neuroectodermal lineage characteristics with reduced capacity to undergo mesodermal differentiation ([@bb0055]; [@bb0070]; [@bb0075]; [@bb0085]; [@bb0120]). These properties are theorized to minimize the risk of ectopic differentiation after CNS transplantation ([@bb0065]). Similar to MSCs MSC-NPs exhibit immunoregulatory and trophic properties both in vitro and in vivo along with upregulation of candidate trophic factors including hepatocyte growth factor (HGF) ([@bb0075]; [@bb0070]; [@bb0040]). Intrathecal (IT) delivery of MSC-NPs during the chronic phase of EAE resulted in neurological recovery associated with increased spinal cord myelination decreased immune infiltration in the CNS and increased recruitment of endogenous progenitor cells ([@bb0075]). Importantly multiple doses rather than a single dose were necessary to demonstrate improvement in neurological function ([@bb0075])

The clinical feasibility of IT MSC-NP treatment in MS was initially investigated in six patients with advanced MS treated with two to five injections of escalating doses of autologous MSC-NPs ([@bb0080]). Patients were followed an average of 7.4 years after initial injection. There were no serious adverse events or safety concerns noted, and the treatments were well-tolerated ([@bb0080]). Four of the six patients showed a measurable clinical improvement following MSC-NP treatment. Based on these pre-clinical and early clinical studies, we initiated an open-label phase I trial using IT autologous MSC-NPs to establish safety and tolerability and to determine efficacy trends in 20 patients with progressive MS. The outcomes of this study support the overall safety and tolerability of this therapeutic approach, in addition to revealing possible evidence of efficacy.

2. Methods {#s0010}
==========

2.1. Study Design and Oversight {#s0015}
-------------------------------

The study was an open-label, single-arm, phase I clinical trial to evaluate safety and tolerability of repeated IT administration of autologous MSC-NPs in 20 patients with progressive MS ([Fig. 1](#f0005){ref-type="fig"}). All study activities were conducted at the Tisch MS Research Center of New York. The study was conducted as an FDA investigational new drug, and is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015}, number [NCT01933802](ctgov:NCT01933802){#ir0020}. The study was approved by Western Institutional Review Board and was conducted in accordance with the Helsinki Declaration. All patients gave written informed consent. An independent external data and safety monitoring board evaluated all safety data.Fig. 1CONSORT flowchart for single-arm, open-label, phase 1 clinical trial of intrathecal autologous MSC-NP in patients with progressive MS.Fig. 1

The treatment phase of the study consisted of three separate IT injections of up to 1 × 10^7^ autologous MSC-NPs spaced three months apart. The dose and dosing schedule were based on a preclinical study in mouse EAE, as well as observed safety and tolerability in an early clinical dose escalation study ([@bb0080]; [@bb0075]). All patients were assessed on the day of treatment, and one day, one week, and one month following each dose. Post-treatment assessments occurred three and six months following the third dose. Long-term safety assessment was scheduled 24 months following the third dose. Although the study was not blinded, all treatments were administered by a single neurologist, and all assessments by a separate neurologist.

Eligible patients had clinically definite SPMS or PPMS with significant disability (EDSS ≥ 3.0) that was not acquired within the 12 months prior to enrollment. The inclusion of patients with a relatively stable disease state was designed to allow better discernment between natural disease progression and treatment-related events. Disease stability was determined by less than a 1.0 point change in EDSS in the 12 months preceding entry into the treatment phase of the study, and lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number and size of T2 lesions) over the same period. Exclusion criteria included patients with cognitive impairment (as determined by mini-mental and PASAT testing), which might impact fully informed consent, and with existing comorbidities such as cancer history that might complicate safety outcomes of the experimental treatment. To minimize additional variables, patients who were already receiving disease-modifying therapies (DMT) upon entering the study continued as a concomitant treatment through the course of the study ([Table 1](#t0005){ref-type="table"}). In subjects receiving concomitant intrathecal methotrexate (IT-MTX), methotrexate and MSC-NPs were administered at least four weeks apart to minimize any effects of this treatment on the cells.Table 1Patient demographics and dosing.Table 1Study subject IDAge/genderMS subtypeBaseline EDSSDisease duration (years)Concomitant DMT (time started)[a](#tf0005){ref-type="table-fn"}Number of MSC-NPs per IT dose1st dose2nd dose3rd dose0165/MSPMS3.514IT-MTX (5 yrs prior)9.6 × 10^6^10 × 10^6^10 × 10^6^0254/FSPMS5.513DMF (2 yrs prior), IVIG (1 yr prior)9.8 × 10^6^10 × 10^6^10 × 10^6^0358/MSPMS6.017IT-MTX (7 yrs prior)10 × 10^6^10 × 10^6^10 × 10^6^0459/MSPMS6.018IVIG (4 wks post)10 × 10^6^10 × 10^6^10 × 10^6^0539/FSPMS6.016NAT (8 yrs prior)7.4 × 10^6^10 × 10^6^10 × 10^6^0651/FSPMS6.025RTX (3 yrs prior)8.0 × 10^6^8.6 × 10^6^5.3 × 10^6^0755/FSPMS6.518RTX (2 yrs prior)7.2 × 10^6^9.2 × 10^6^10 × 10^6^0853/FSPMS6.527IFN-β (6 yrs prior)10 × 10^6^10 × 10^6^10 × 10^6^0956/MPPMS6.522None9.7 × 10^6^9.2 × 10^6^8.9 × 10^6^1037/FPPMS6.514IT-MTX (2 yrs prior)10 × 10^6^10 × 10^6^10 × 10^6^1127/FSPMS7.010RTX (2 wks post)10 × 10^6^10 × 10^6^10 × 10^6^1252/FSPMS7.532IT-MTX (11 yrs prior)7.2 × 10^6^7.0 × 10^6^10 × 10^6^1345/FSPMS7.511None9.6 × 10^6^9.8 × 10^6^9.7 × 10^6^1434/FSPMS7.512RTX (5 yrs prior)7.0 × 10^6^10 × 10^6^9.6 × 10^6^1550/FSPMS7.519RTX (6 yrs prior)8.9 × 10^6^10 × 10^6^10 × 10^6^1663/FSPMS8.032IT-MTX (6 yrs prior)10 × 10^6^9.5 × 10^6^8.9 × 10^6^1761/FSPMS8.032None9.3 × 10^6^9.0 × 10^6^10 × 10^6^1850/MPPMS8.010RTX (2 yrs prior)8.5 × 10^6^10 × 10^6^9.9 × 10^6^1936/FSPMS8.020IT-MTX (11 yrs prior)10 × 10^6^9.6 × 10^6^7.1 × 10^6^2035/MPPMS8.513None10 × 10^6^10 × 10^6^7.8 × 10^6^[^1][^2]

2.2. Clinical Assessments {#s0020}
-------------------------

All study subjects underwent baseline exams that included EDSS, T25FW, nine-hole peg test, paced auditory serial addition test (PASAT), multiple sclerosis quality of life questionnaire, physical exam, neurological exam, and headache pain scale. Additional safety testing was performed as suggested by the FDA. Follow-up exams and neurological assessments were conducted at a pre-designated frequency after each dose in order to assess adverse events, and three and six months after the third dose to compare with pre-treatment baseline. The numerical headache pain scale from 0 (no pain at all) to 10 (pain as bad as it can be) was completed pre-treatment, and 24 h, 3 days, 5 days, 1 week, 2 weeks, and 1 month following each treatment. Headaches were classified as "mild" for pain rated between 0 and 3, "moderate" for pain rated between 4 and 7, and "severe" for pain rated between 8 and 10.

Brain MRI scans with and without gadolinium enhancement were performed at baseline, two months after the first dose, and three months after the third dose to assess safety and document any change. All scans were read by visual inspection by independent neuro-radiologists who were blinded to the sequence of MRIs in relation to treatment. Changes in T2 lesion burden, T1 black holes, brain volume, and gadolinium-enhancing lesions were documented.

To address bladder function, a pertinent history of symptoms was taken and any use of medications affecting bladder function was noted. All subjects underwent urodynamic testing at baseline and three months after the third dose. All urodynamic testing was performed in the same laboratory and results interpreted by a single neuro-urologist. The following parameters were recorded: PVR, cystometry with simultaneous measurements of bladder, urethral and subtracted rectal pressures for first sensation, maximum bladder capacity, urethral pressure profile with functional length measurement and maximum closing pressure. Bladder pressure was assessed with filling and sphincter relaxation and synergic voiding assessed. Urinary peak flow rate was also measured.

Muscle strength was graded by a single neurologist using Medical Research Council (MRC) scale as follows: 0, no contraction (plegic); 1, trace of contraction; 2, active movement, gravity eliminated; 3, active movement against gravity; 4, active movement against gravity and resistance; 5, normal strength ([@bb0125]). Muscles that were scored included deltoid, biceps brachii, triceps, wrist extensors, digit extensors and flexors in the upper limb and iliopsoas, hip abductors/adductors, quadriceps, hamstrings, ankle dorsi and planter flexors, and toe flexors and extensors in the lower limbs. Marked improvement was defined as improvement in multiple muscle groups and increased muscle function. Moderate improvement defined as increased strength in at least one muscle with functional change. Mild improvement defined as increased strength in at least one muscle without functional change.

2.3. Preparation of Autologous MSC-NP Cells {#s0025}
-------------------------------------------

Clinical-grade autologous MSC-NPs for each subject were isolated, expanded, and analyzed under a current good manufacturing practice (cGMP)-compliant process in a clean-room facility at the Tisch MS Research Center of New York. As previously described ([@bb0070]; [@bb0080]), MSCs were isolated based on plastic adherence from the mononucleated cell fraction from a 20 ml sternal bone marrow aspirate, and expanded ex vivo in MSC growth medium (Lonza) supplemented with 2 mM GlutaMAX™I CTS™ (Thermo Fisher Scientific) and 10% double-filtered autologous serum collected from peripheral blood of each study participant. Cells were incubated in a humidified 37 °C incubator at 5% CO~2~ and 5% O~2~. MSCs were cryopreserved after two and three passages, generating a stock of cells sufficient for multiple subsequent expansions. For each treatment, a portion of MSCs were thawed, expanded for two to three more passages, then cultured for two to three weeks in neural progenitor maintenance medium (Lonza) supplemented with 20 ng/ml each of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to generate neural progenitors (MSC-NPs). Just prior to the injection, MSC-NPs were collected, washed, counted, and resuspended in preservative-free saline for immediate intrathecal administration. The target cell number was between 5 × 10^6^ and 1 × 10^7^ cells. The maximum dose of 1 × 10^7^ cells per treatment was not always attained due to the individual growth characteristics of each batch of MSC-NPs ([Table 1](#t0005){ref-type="table"}).

Quality and safety testing was conducted at multiple steps during MSC-NP manufacturing to ensure quality, sterility and batch-to-batch consistency. Bone marrow-derived MSCs were tested for MSC characteristics including growth, morphology, cell surface expression (CD105^+^/CD73^+^/CD90^+^/CD45^−^/CD34^−^/CD14^−^/CD20^−^/HLA-DR^−^), and in vitro osteogenic and adipogenic differentiation potential as determined by alizarin red or Oil Red O positivity, respectively, as described previously ([@bb0070]). After each MSC expansion, chromosome analysis was performed on a minimum of 20 DAPI-banded metaphases and all metaphases were fully karyotyped (Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center). MSC-NPs generated from MSCs were assessed based on neurosphere morphology, cell number, and cell viability by trypan blue. Sterility was assessed by qPCR with Microbial DNA qPCR Assays Pan Bacteria 3 and Pan Aspergillus/Candida (Qiagen) using DNA extracted from MSC-NP conditioned media. Final product sterility was confirmed by gram stain and by 14-day liquid culture.

Confirmation of neural lineage differentiation of MSC-NPs was performed by TaqMan® Gene Expression Assays (Thermo Fisher Scientific) as previously described ([@bb0070]) to confirm neural lineage gene upregulation of C-X-C motif chemokine receptor 4 (CXCR4) (Assay ID: Hs00607978_s1), Sry-box 2 (SOX2) (Assay ID: Hs01053049_s1), toll like receptor 2 (TLR2) (Assay ID: Hs01872448_s1), and leukemia inhibitory factor (LIF) (Assay ID: Hs01055668_m1) and mesodermal lineage gene downregulation of smooth muscle isoform of alpha 2 actin (ACTA2) (Assay ID: Hs00426835_g1) and CD90 (THY1) (Assay ID: Hs00264235_s1) in MSC-NPs compared to the MSCs from which they were derived. Gene expression was normalized to IPO8 endogenous control (Hs00183533_m1) and relative quantification was determined by delta delta Ct analysis of MSC-NPs compared to the MSCs using RQ Manager software (Applied Biosystems). Final product testing specified \>2-fold up- or down-regulation of at least 4 of the 6 genes on the panel for product release. Additional gene targets analyzed included hepatocyte growth factor (HGF) (Assay ID: Hs00300159_m1), nestin (NES) (Assay ID: Hs00707120_s1), neurofilament medium (NEFM) (Assay ID: Hs00193572_m1), and glial fibrillary acidic protein (GFAP) (Assay ID: Hs00909238_g1).

2.4. Treatment Procedure {#s0030}
------------------------

Injections of autologous cell suspensions were performed intrathecally via standard lumbar puncture at the L3-L4 level using a 24 gauge non-traumatic spinal needle. Cerebrospinal fluid (CSF) (3--5 ml) was withdrawn, and MSC-NPs were resuspended in 2 ml of sterile saline and injected into the intrathecal space, followed by a flush of 2 ml of saline. In eight of the subjects, cells were administered intrathecally via the in-dwelling access port of their implanted baclofen pump. For all IT-MSC-NP treatments, prophylactic IV infusion of antibiotics (80 mg of tobramycin and 500 mg of vancomycin) was co-administered to minimize any risk of meningitis. Tobramycin or vancomycin had no effect on MSC-NP cell viability or proliferation in vitro (data not shown).

2.5. Statistical Analysis {#s0035}
-------------------------

The Wilcoxon Signed-Rank test was used to compare median EDSS from baseline (at the time of the first dose) to the final time point 6 months post-3rd dose. The Wilcoxon Rank Sum test was used to assess the change from baseline to 6 months between ambulatory patients (baseline EDSS ≤ 6.5) and non-ambulatory patients (baseline EDSS ≥ 7.0). The Fisher\'s exact test was used to assess the association between EDSS improvement (i.e. at least a 0.5 point decrease in EDSS or more at six months post-treatment vs. no change or increase in EDSS) and baseline ambulatory status, as well as the association between EDSS improvement and disease subtype (i.e., SPMS vs. PPMS). All *p*-values are two-sided with statistical significance evaluated at the 0.05 alpha level. Statistical analysis was performed in R Version 3.3.1 (R Core Team, Vienna, Austria).

3. Results {#s0040}
==========

Demographics of the 20 study subjects are shown in [Table 1](#t0005){ref-type="table"}. The study cohort had a mean EDSS of 6.8 (range 3.5 to 8.5) and mean disease duration of 18.8 years (range 10--32 years). Only six of the twenty patients were male and 80% of the patients had SPMS. Half of the study subjects were non-ambulatory at the time of enrollment (EDSS ≥ 7.0), eight subjects required assistance for ambulation (EDSS 6.0 to 6.5), and two subjects were able to ambulate without assistance (EDSS 3.5 to 5.5). There were no significant associations observed between ambulatory status and patient demographics (age, gender, disease subtype, or disease duration).

The primary objective of the phase I study was to test safety and tolerability of autologous MSC-NPs administered intrathecally in MS patients. MSC-NPs were administered every three months for a total of three doses of up to 1 × 10^7^ cells per dose. Variation in the final dose, which averaged 9.4 × 10^6^ cells (range 5.3 × 10^6^ to 1 × 10^7^ cells) was dependent on the individual growth characteristics of each batch of MSC-NPs ([Table 1](#t0005){ref-type="table"}). There was no correlation between the number of cells administered or cell viability with age or disease type. All patients received the target dose range of five to ten million cells, and 70% received the maximum dose. Each batch of MSC-NPs was confirmed to have neural lineage characteristics prior to injection (Supplementary Fig. 1).

There were no serious adverse events or hospitalizations associated with IT MSC-NP treatment ([Table 2](#t0010){ref-type="table"}). Specifically, we did not observe any cases of chemical or infectious meningitis. The most frequently observed minor adverse events consisted of transient headaches and fever occurring within 24 h after the treatment in 17 out of 20 patients (85%). Of the 60 total treatments, the majority (34/60, or 57%) were associated with mild to moderate headaches, and 15% (9/60) were associated with severe headaches. All headaches resolved within 1 week after over-the-counter treatment with acetaminophen, ibuprofen, naproxen, or no treatment. The exception was subject \#17 who experienced headache of mild to moderate severity that persisted for one month that was determined to be a consequence of the lumbar puncture procedure (spinal headache). In addition, 5 patients experienced low-grade fever (below 100 °F) 24 h after treatment that resolved in all cases within 48 h without any treatment. Overall, fever was associated with 9 out of 60 treatments (15%). The incidence of headache or fever did not differ among the 3 IT administrations. Upon specific questioning, none of the adverse events were severe enough for any study subject to choose to discontinue participation in the trial.Table 2Adverse events during or after IT MSC-NP treatment.Table 2EventsNumber out of 20 participants (% of participants)Any event18 (90%)Any severe event, hospitalization or death0 (0%)Any headache17 (85%) Mild/moderate headache11 (55%) Severe headache6 (30%)Fever5 (25%)Urinary tract infection9 (45%)Fatigue2 (10%)MS exacerbation0 (0%)Post lumbar puncture headache1 (5%)Miscellaneous (renal calculus)1 (5%)Depression1 (5%)

The safety data was further supported by a lack of any change in brain MRI scans during the study. Specifically, no new T2 lesions or changes in disease burden were observed. These data demonstrate that multiple IT administration of MSC-NPs was well tolerated and was associated with short-term safety.

The study design finalized with FDA guidance was not blinded, and there were no placebo controls. All study subjects were monitored for changes in clinical status. The primary post-treatment clinical assessments were conducted at three and six months following the third treatment and compared to baseline (pre-treatment) in order to determine trends in efficacy. Of the 20 study subjects, 15 (or 75%) demonstrated neurological improvement associated with IT MSC-NP treatment. Improvements were documented in the following areas: EDSS, MRC muscle strength scale, timed 25-ft walk (T25FW), and/or bladder function. Of the remaining subjects, two showed disease worsening despite the treatment, and three subjects showed no change.

Muscle strength testing by MRC muscle strength scale showed that 14 of the 20 subjects (70%) showed objective increase in muscle strength ([Table 3](#t0015){ref-type="table"}) with most of the subjects (13 out of 14) demonstrating improvement in lower limb (LL) strength. Only one of the 14 patients had increased strength limited to the upper limbs (UL). In addition to greater muscle strength, four out of the ten ambulatory subjects showed a \>20% improvement in T25FW speed compared to pre-treatment baseline ([Table 4](#t0020){ref-type="table"}). Two additional study subjects (\#11 and \#12) who were non-ambulatory at baseline were able to perform the walk test post-treatment, albeit with bilateral use of assistive devices.Table 3Muscle strength at baseline and three months post-third IT MSC-NP treatment.Table 3Study Subject IDUpper limb (UL)\
Lower limb (LL)Muscle strength (weakest-strongest)[a](#tf0010){ref-type="table-fn"}DescriptionBaselinePost-treatmentLeftRightLeftRight01UL5555Marked improvement in right LL with normalization of motor strength.LL53--45502UL5555Marked improvement bilaterally in LL with normalization of motor strength.LL4--53--55503UL4--554--55Marked improvement in left LL.LL1--553--5504UL52--553--5Marked improvement bilaterally in LL with modest improvement in right UL.LL4--53--554--505UL5555Moderate improvement bilaterally in hip flexors.LL4--54--54--54--506UL4--554--55Moderate improvement in bilateral hip flexors.LL2--44--53--44--507UL54--554--5No change in motor strength.LL2--52--42--52--408UL4--5555Moderate improvement in left UL and bilaterally in LL.LL2--43--52--5509UL54--54--55Mild improvement in right UL and LL. Weaker left digit extensors.LL4--52--54--53--510UL454--55No overall change in motor strength.LL13--523--411UL5555Moderate improvement bilaterally in LL.LL2--42--33--52--412UL53--553--5Moderate improvement in right LL.LL2--41--22--41--213UL3--452--35Increased weakness of left UL and right LL.LL1--24--51--23--514UL4--54--54--54--5No change in motor strength.LL2--42--42--42--415UL4--54--54--54--5No change in motor strength.LL2--42--52--42--516UL4--54--54--54--5No change in motor strength.LL0--22--50--22--517UL453--45Mild improvement in right quadriceps.LL0000--218UL4--554--55Mild improvement in right quadriceps.LL1--21--21--21--419UL5555Moderate improvement bilaterally in LL.LL021--22--420UL2--32--44--52--4Moderate improvement in left UL.LL0000[^3]Table 4Timed 25-ft walk results at baseline and three months post-third IT MSC-NP treatment.Table 4Study subject IDT25FW time at baseline (seconds)T25FW time post-treatment (seconds)[a](#tf0015){ref-type="table-fn"}% Improvement of T25FWAmbulatory at baseline016.05.017%0210.85.946%0312.79.624%048.46.126%0512.212.6-3%0618.318.6−2%0728.127.04%0853.423.955%0925.322.013%1097.4--n/aNon-ambulatory at baseline[b](#tf0020){ref-type="table-fn"}11--39.1n/a12--165.8n/a[^4][^5][^6]

EDSS was assessed every three months starting at baseline, at the time of second and third dosing, and three and six months post third dose ([Fig. 2](#f0010){ref-type="fig"}). Overall, there was a decrease in median EDSS from 6.8 at baseline to 6.5 six months post-third treatment (*p* = .058). It was notable that the minimum EDSS score was lower at the final time-point (minimum EDSS of 1.5) than at baseline (minimum EDSS of 3.5). Eight study subjects (40%) demonstrated at least a 0.5 point improvement in EDSS six months post-treatment, with four of the eight subjects showing an improvement of 2.0 or greater positive change compared to baseline. Ten study subjects showed continued stable EDSS throughout the course of treatment, and two study subjects had evidence of disease progression as determined by a decline in EDSS. There was a statistically non-significant change in EDSS score from baseline to six months post-treatment in subjects who were ambulatory at baseline (median difference 0.5 (0.0;2.0)) compared to non-ambulatory patients (median difference 0.0 (0.0;0.0)) (*p* = .097). Similarly, a higher proportion of ambulatory patients (60%) had an EDSS improvement of 0.5 or more compared to non-ambulatory patients (20%) (*p* = .170). There was also a statistically non-significant trend for a higher percentage of improvement (≥0.5 on EDSS vs. no improvement) in SPMS patients (50%) compared to patients with PPMS (0%) (*p* = .117).Fig. 2Changes in EDSS score after MSC-NP administration. EDSS scores are depicted for each of the 20 study subjects over the duration of the study (months). IT MSC-NP treatments were initiated at time 0 months. Black bars indicate EDSS scores during the one-year interval prior to receiving the first dose (months −12 to 0). Eight subjects showed ≥0.5 point reduction in EDSS (yellow bars), 10 subjects showed no change in EDSS (blue bars) and 2 subjects showed disease worsening (red bars). Overall, in the 20 study subjects there was a decrease (*p* = 0.058) in median value from baseline (month 0) EDSS 6.8 to final post-treatment (month 12) EDSS of 6.5 as determined by Wilcoxon Signed-Rank test.Fig. 2

To determine whether bladder function was affected by IT MSC-NP treatment, we conducted urodynamic testing in all study subjects at baseline and three months post-third treatment, in addition to taking a urinary function history and noting use of bladder medications. One subject had normal bladder function at baseline, and a second subject neglected to complete baseline urodynamics so they were not included in the bladder function analysis. Of the remaining 18 study subjects, nine subjects (50%) demonstrated either symptomatic and/or urodynamic improvement in bladder function post treatment ([Table 5](#t0025){ref-type="table"}). Improvement was evident either by a \>20% improvement in bladder capacity at three-month follow-up compared to baseline, and/or by discontinuation of bladder medication and documented improvement in bladder function upon questioning. We hypothesize that improvement of bladder function may reflect MSC-NP-mediated repair and regeneration in spinal cord areas proximal to the area of injection.Table 5Bladder function improvements following IT MSC-NP treatment.Table 5Study subject ID[a](#tf0025){ref-type="table-fn"}Baseline bladder FunctionPost-treatment bladder function01Micturition urgency treated with tolterodine. UD consistent with mild BPH.Improved urgency and D/C tolterodine. No change in urodynamics.02Incomplete emptying with mild urgency. PVR of 274 ml.Asymptomatic. PVR normalized to \<70 ml.03Urgency and hesitancy with incomplete emptying. Treated with tamsulosin. UD testing showed neurogenic bladder with outlet obstruction and PVR of 200 ml.Improved urgency and emptying with D/C tamsulosin. UD showed improved detrusor-sphincter dysfunction with PVR of 100 ml.05Urgency and retention requiring IC ×3 daily. Treated with oxybutynin and tamsulosin. UD showed detrusor overactivity with PVR of 400 ml.Improved urgency and able to void without IC. D/C medications. Improved detrusor contractility on UD with 40% reduction of PVR.07Urgency treated with mirabegron. UD showed neurogenic bladder with detrusor overactivity and bladder capacity of 100 ml.Improved urgency. UD showed improved detrusor overactivity and increased bladder capacity to 300 ml.11Urgency with incontinence. Treated with mirabegron. UD showed severe detrusor sphincter dyssynergia with detrusor overactivity. Bladder capacity of 200 ml.Improved urgency with no incontinence. UD confirmed improved detrusor function with bladder capacity increased to 600 ml.12Urgency, incomplete emptying, and double voiding. UD showed PVR of 270 ml.Asymptomatic with no double voiding. UD showed improved PVR by 20%.15Urgency with incontinence requiring diapers. Treated with tamsulosin. UD showed severe detrusor overactivity with bladder capacity of 177 ml.Improved urgency and incontinence. D/C diaper use. UD showed decreased bladder pressures and detrusor activity with increased bladder capacity by 70%.16Urgency with incontinence and incomplete emptying. Treated with tamsulosin. UD showed detrusor overactivity and reduced bladder capacity of 107 ml.Improved urgency and bladder emptying with absence of incontinence. D/C tamsulosin. UD showed normalized detrusor activity with increased bladder capacity to 667 ml.[^7][^8]

As intact cognition function was a requirement to participate in this study, we did not observe any changes on PASAT testing. There were no efficacy trends in upper limb function as determined by the nine-hole peg test, although one patient who could not perform the test pre-treatment showed measurable improvement in the non-dominant limb (Supplementary Table 1). Overall, we observed that subjects with improved EDSS after IT MSC-NP treatment also showed consistent improvement in muscle strength, T25FW, and/or bladder function (Supplementary Table 2).

4. Discussion {#s0045}
=============

This single center, open-label phase I study in patients with MS shows that repeated administration of intrathecally-injected bone marrow derived MSC-NPs is safe and well tolerated. Consistent with previous reports, intrathecal cell therapy is associated with transient headaches and mild febrile reactions in the immediate post-injection period ([@bb0015]; [@bb0080]; [@bb0095]; [@bb0135]). Importantly, there were no serious adverse events associated with this treatment. Despite having the option to discontinue treatment at will, all 20 of the study subjects tolerated and completed the 60 planned treatments.

Although this open-label single arm study was not designed to establish efficacy, we report our observations. Improvement of established disability was seen in 40% of patients as assessed by a decrease in post-treatment EDSS scores compared to baseline. This possible efficacious therapeutic effect is confounded by a lack of comparator placebo arm. However, improvement was also observed in muscle strength testing in at least one muscle group in 70% of patients, which was associated with improved ambulatory speed and less measurable disability in 40% of all patients. Consistent with our previous observations ([@bb0080]), post-treatment improvements in bladder function were observed in 50% of study subjects as determined by decreased symptomology, decreased medication use or improved urodynamic values. These efficacy trends were particularly encouraging given that the patient selection was not particularly suited to determine efficacy as the majority of patients had advanced disability (mean EDSS at baseline was 6.8) and had long-standing disease (mean disease duration over 18 years). Statistical trends in the data suggest that the therapeutic response to IT MSC-NP treatment may be most evident in ambulatory patients who have SPMS, in contrast to those who are non-ambulatory or who have PPMS. However, we acknowledge that the open-label study design of this phase I trial was not primarily setup to determine efficacy but to ensure safety. The overriding safety concerns with the use of multiple IT cell injections, including the possible development of acute hydrocephalus by the infusion of IT cells or risk of tumor development, resulted in close initial monitoring and a staggered initial treatment of patients. Despite the shortcomings of the efficacy assessments, our positive results are noteworthy for a phase I study in a population of advanced MS patients, and potentially represent a new therapeutic option for MS patients with established disability.

A number of key factors may have contributed to our observations using IT MSC-NP treatment. First, the experimental design included multiple rather than single dosing of MSC-NPs, as a result of our previous work in the EAE animal model of MS ([@bb0075]). Likewise, in other neurological diseases such as amyotrophic lateral sclerosis (ALS), multiple dosing of intrathecal MSCs has been incorporated into early phase I/II study designs as supported by pre-clinical models ([@bb0145]; [@bb0180]; [@bb0205]). Based on the proposed trophic mechanism of action of MSC-NPs, we hypothesize that multiple doses of cells may be necessary for the sustained production of immunomodulatory and trophic factors in order to exceed a therapeutic threshold ([@bb0075]; [@bb0205]). We found that MSC-NPs express and secrete a number of trophic factors including HGF, GDNF, IGF, and LIF ([@bb0070]), all of which have been shown previously to mediate various aspects of neural repair including recruitment of endogenous progenitors ([@bb0010]; [@bb0045]; [@bb0090]; [@bb0210]; [@bb0215]). In addition, the release of immunomodulatory factors by intrathecally transplanted MSC-NPs may specifically target the compartmentalized inflammation such as astrocyte and microglial activation characteristic of progressive MS ([@bb0115]).

Another important aspect of this study was the use of the intrathecal route of administration for cell delivery. Although intravenous administration of bone marrow MSCs was capable of suppressing EAE through immunomodulatory mechanisms, it has not been established that a sufficient number of cells cross the blood-brain barrier to directly impact reparative mechanisms in the CNS ([@bb0005]; [@bb0060]; [@bb0100]). Indeed, early clinical trials testing intravenous autologous MSCs have shown limited therapeutic benefit in MS ([@bb0025]; [@bb0035]; [@bb0110]). Because physical disability in MS is likely a manifestation of spinal cord disease, the IT route of administration maximizes the therapeutic potential for effect in the spinal cord. The safety and feasibility of this approach is supported by initial open-label clinical studies investigating autologous MSCs or MSC-NPs in MS administered via the IT route ([@bb0015]; [@bb0080]; [@bb0095]; [@bb0135]; [@bb0190]). Although some side effects associated with meningeal irritation were initially reported, particularly in one patient who received a very high cell dose ([@bb0190]), IT cell delivery is generally well tolerated. Lastly, and perhaps most importantly, MSC-NPs were freshly harvested from cell culture and immediately administered to the patient, thus addressing a recent concern regarding impaired therapeutic functionality of cryopreserved cells thawed at bedside ([@bb0050]; [@bb0140]).

In conclusion, this study shows that intrathecal therapy with MSC-NPs is safe and well tolerated in patients with MS. Improvement of neurological disability was noted in a number of patients. These findings have led to the initiation of a FDA-approved randomized, placebo controlled and blinded phase II study in a larger group of patients to determine efficacy.
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[^1]: Abbreviations: DMT, disease-modifying therapy; IT, intrathecal; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive multiple sclerosis; IT-MTX, intrathecal methotrexate; RTX, rituximab; NAT, Natalizumab; DMF, dimethyl fumarate; IVIG, intravenous immunoglobulin; IFN-β, interferon-β-1a.

[^2]: Time in number of years (yrs) or weeks (wks) the concomitant DMT was started either prior to or following (post) the first IT MSC-NP treatment.

[^3]: Muscle strength graded MRC scale as follows: 0, no contraction (plegic); 1, trace of contraction; 2, active movement, gravity eliminated; 3, active movement against gravity; 4, active movement against gravity and resistance; 5, normal strength. Muscle strength indicated as weakest to strongest muscle.

[^4]: Abbreviations: T25FW, timed 25-ft walk; "-", test not performed because subject not ambulatory; n/a, not applicable.

[^5]: Pre- and post-walk times were determined using the same assistive device (if any) for each individual study subject.

[^6]: Remaining non-ambulatory study subjects (ID\# 13--20) not shown due to lack of change in ambulation post-treatment.

[^7]: Abbreviations: UD, urodynamics; IC, intermittent catheterization; D/C, discontinued; PVR, post-void residual volume; BPH, benign prostatic hypertrophy.

[^8]: Bladder function details shown only for the 9 study subjects who demonstrated bladder function improvement post-treatment.
